AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026

AtaiBeckley Inc.

2026-Q1 EPS reported -$0.08 revenue$954,000

Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.
BPL-003 Phase 3 ReConnection program (two studies, ~580 patients) to begin Q2 2026.
VLS-01 Phase 2 Elumina topline results expected in Q4 2026.
EMP-01 Phase 2a showed consistent improvements in Social Anxiety Disorder.
Appointed Michael Faerm as CFO effective March 9, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AtaiBeckley Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 12, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026 and provided program and business updates.

View on SEC.gov

572 earnings releases filed in the last 30 days. Browse all earnings releases →

AtaiBeckley Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-020708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.